Jeff Bockman, Expert Advisor and EVP, Oncology, Lumanity, and Head of Oncology Center of Excellence at Lumanity, shared a post on LinkedIn:
“Well, like the big talks that either lead to paradigm changes or to failed programs, at AACR or ASCO or today, at Society for Immunotherapy of Cancer (SITC), I can say I was there…
Let’s hope this is a significant advance for patients across many cancers and patient settings.
And it will be interesting to see how the horse race ends, given how many of these bispecifics there are.”
More posts about SITC.